Published in

Elsevier, Journal of Pharmaceutical and Biomedical Analysis, 3(53), p. 693-697

DOI: 10.1016/j.jpba.2010.03.028

Links

Tools

Export citation

Search in Google Scholar

Determination of Z-3,5,4 '-trimethoxystilbene in rat plasma by a simple HPLC method: Application in a pre-clinical pharmacokinetic study

Journal article published in 2010 by Hai-Shu Lin, Wei Zhang ORCID, Mei Lin Go, Qiu-Yi Choo, Paul C. Ho
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

A simple HPLC method had been developed and validated to quantify Z-3,5,4'-trimethoxystilbene (Z-TMS), a phyto-stilbene with potent anti-cancer activities in rat plasma. Chromatographic separation was achieved on a reversed phase-HPLC column, which was protected by a guard column through a 13.5-min gradient delivery of a mixture of acetonitrile and water at a flow rate of 1.5 ml/min at 50 degrees C. The UV absorbance at 300 nm was recorded. Z-TMS and E-stilbene (internal standard) eluted at 8.8 and 9.3 min, respectively. The calibration curve was linear within the range of 33-2500 ng/ml (R(2)>0.9995) and 10 ng/ml was the lower limit of detection. The intra- and inter-day precisions were good and the relative standard deviation was all lower than 10%. The analytical recovery of Z-TMS in plasma ranged from 94.6+/-9.1% to 97.0+/-2.1%. This HPLC method was successfully applied to assess the pharmacokinetic profile of Z-TMS in Sprague-Dawley rats using hydroxypropyl-beta-cyclodextrin (HP-beta-CyD) as a dosing vehicle. Although Z-TMS displayed negligible oral bioavailability, it had a fairly long terminal elimination half-life, abundant plasma drug exposure and limited clearance following intravenous administration. As Z-TMS had favorable intravenous pharmacokinetic profile, further investigation on its potential as a cancer chemotherapeutic agent is warranted.